Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals, Inc. (CRVS) is a healthcare company (biotechnology) based in the United States. The share price is $10.24, down 3.40% on the day, which values the company at $863.78M. Price as of 17 Nov 2026, 20:34 UTC, from Yahoo Finance.

Key facts

Share price
$10.24−3.40% today
Market value
$863.78M
200-week average
$6.0270% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Corvus Pharmaceuticals, Inc. in more detail

CRVS trades at -9.3× next year's expected earnings. It sits 70% above its 200-week average of $6.02.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

1 of the superinvestors tracked here hold CRVS, including Peter Kolchinsky (0.1% of the portfolio).

Superinvestors holding CRVS

1 of the investors tracked here report a position in their latest 13F filing.

Corvus Pharmaceuticals, Inc. (CRVS): questions and answers

What is Corvus Pharmaceuticals, Inc.'s market cap?

Corvus Pharmaceuticals, Inc. is valued at $863.78M at a share price of $10.24.

Is CRVS above its 200-week moving average?

Yes. CRVS is 70.2% above its 200-week average of $6.02. Long-term investors watch that line because strong companies rarely trade below it for long.

Does CRVS pay a dividend?

Corvus Pharmaceuticals, Inc. does not currently pay a regular dividend.

Which famous investors own CRVS?

In their latest quarterly filings, Peter Kolchinsky (0.1% of the portfolio) hold CRVS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Corvus Pharmaceuticals, Inc. (CRVS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CRVS

Underlying data: Yahoo Finance; company filings with the SEC.